Is Medline (MDLN) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?

Medline Inc. (NASDAQ:MDLN) is one of the best healthcare stocks to buy with highest upside potential. Barclays cut the price target on Medline Inc. (NASDAQ:MDLN) to $45 from $50 on June 1, maintaining an Overweight rating on the shares. The firm stated that it believes factors such as inflationary pressure weighing on the margin outlook, less upside to fiscal Q1 estimates, and two secondaries have brought the company’s valuation “to a more palatable level.” According to Barclays, the stock is “poised for multiple expansion post war”, and it expects the company to “continue racking up share in the interim.”

Medline Inc. (NASDAQ:MDLN) also received a rating update from Tigress Financial on May 13. The firm lifted the price target on the stock to $62 from $60 while maintaining a Buy rating on the shares. It stated that the company’s ongoing transition from a traditional medical distributor to “a data-rich, AI-enabled supply chain partner” creates “near-term noise,” but “a long-term buying opportunity.”

Medline Inc. (NASDAQ:MDLN) provides medical-surgical products and supply chain solutions. The company’s operations are divided into the Medline Brand and Supply Chain Solutions segments.

While we acknowledge the risk and potential of MDLN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MDLN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1